Agents for gene therapy of cerebrovascular disorders
AssigneeAnGes MG, Inc.
InventorsRyuichi Morishita, Munehisa Shimamura
Life of this patent
Estimating the term…
Abstract
The present invention provides novel methods for treating cerebrovascular disorders, in which HGF is overexpressed by introducing an HGF gene. The methods of this invention using an HGF gene enable active treatment of cerebrovascular disorders, such as cerebral infarction, by gene transfer, and enable the maintenance of neuronal function and the suppression of infarcted areas in patients for whom appropriate treatment methods were unavailable until now.
Claims26
An agent for treating or preventing a cerebrovascular disorder, wherein the agent comprises a nucleic acid encoding a protein effective as a hepatocyte growth factor.
An agent comprising a hemagglutinating virus of Japan (HVJ)-envelope vector, wherein the HVJ-envelope vector comprises:
- an isolated nucleic acid encoding a hepatocyte growth factor protein enclosed within an HVJ-envelope;
- and
- is free of liposome.
An agent comprising an HVJ (hemagglutinating virus of Japan)-envelope vector, wherein the HVJ-envelope vector comprises:
- an isolated nucleic acid encoding a hepatocyte growth factor operably linked to a promoter, which has been enclosed within an HVJ-envelope, wherein the HVJ-envelope vector has a diameter less than that of an HVJ-liposome.
A method for reducing an infarcted area of a cerebral infarction comprising:
- administering an agent comprising an HVJ-envelope vector by direct injection into the subarachnoid space of a subject prior to the occurrence of said cerebral infarction, wherein said HVJ-envelope vector comprises:
- an isolated nucleic acid encoding a hepatocyte growth factor protein enclosed within an HVJ-envelope;
- and
- is free of liposome, wherein said method results in a reduction of the infarcted area.
A method for reducing an infarcted area of a cerebral infarction comprising:
- administering an agent comprising an HVJ-envelope vector by direct injection into the subarachnoid space of a subject, wherein said HVJ-envelope vector comprises:
- an isolated nucleic acid encoding a hepatocyte growth factor operably linked to a promoter, which has been enclosed within an HVJ-envelope, wherein the HVJ-envelope vector has a diameter less than that of an HVJ-liposome;
- and
- wherein said method results in a reduction of the infarcted area.
A method for reducing an infarcted area of a cerebral infarction comprising:
- administering an agent comprising an HVJ (hemagglutinating virus of Japan)-envelope vector by direct injection into the subarachnoid space of a subject prior to the occurrence of said cerebral infarction, wherein said HVJ-envelope vector comprises:
- an isolated nucleic acid encoding a hepatocyte growth factor operably linked to a promoter, which has been enclosed within an HVJ-envelope and is prepared by mixing an inactivated HVJ which has been inactivated by UV irradiation with the isolated nucleic acid encoding hepatocyte growth factor operably linked to a promoter in the presence of a surfactant;
- and
- inducing a cerebral infarction in the subject, wherein said method results in a reduction of the infarcted area.
Dependencies are inferred from the claim text.